Date / Time
The goal of this activity is to improve the knowledge, confidence, and competence of learners to provide optimal care for their patients with bladder cancer.
This program is intended for medical oncologists, and other healthcare providers who care for patients with bladder cancer.
Upon completion of this activity, participants should be able to:
- Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma, considering the available evidence, and patient and disease characteristics
- Incorporate guideline and expert recommendations to optimally manage adverse events associated with the use of immune checkpoint inhibitors
- Evaluate biomarkers that accurately predict treatment response and assist in patient selection for personalized therapy
- Plan therapy for patients with urothelial carcinoma and disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
- Describe the available data and emerging therapeutic options for maintenance therapy after induction chemotherapy in advanced urothelial carcinoma
- Discuss ongoing clinical trials investigating targeted systemic therapies and immune checkpoint inhibitor–based combinations for patients across the urothelial carcinoma disease spectrum
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.